Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators

Department of Cardiology/Thoraxcenter, University Hospital Groningen, The Netherlands.

OBJECTIVES: This study was conducted to test the hypothesis that angiotensin-converting enzyme (ACE) inhibition reduces myocardial ischemia and related events after myocardial infarction (MI). BACKGROUND: The oxygen demand/supply ratio of the myocardium is influenced by angiotensin II as a result of its arterial vasoconstrictive and inotropic effects and through its interaction with the sympathetic nervous system. METHODS: We studied 244 patients who had been included in a double-blind, randomized, placebo-controlled, post-MI, ACE inhibition intervention study (Captopril and Thrombolysis Study [CATS]). All patients underwent exercise testing before and 3 and 12 months after hospital discharge. After 1-year double-blind treatment, all patients continued receiving single-blind placebo for 1 month. RESULTS: Total exercise time increased in both groups after 3 months (placebo: +86 +/- 13 s; captopril: +69 +/- 12 s, p = 0.8 between groups) and increased further after 1 year (placebo: +13 +/- 11 s; captopril: +33 +/- 13 s, p = 0.7 between groups). There were also no differences in mean ST segment depression. During the 12 months, significantly fewer ischemia-related events occurred in the captopril group (82 vs. 52, p = 0.015). This difference was found between 3 and 12 months but not during the first 3 months. After withdrawal from double-blind medication, nine ischemic events were reported in teh captopril group compared with one in the placebo group (p = 0.006 between groups). CONCLUSIONS: The present data show that captopril may reduce the incidence of ischemia-related events after MI, which becomes apparent after 3 months. However, no anti-ischemic effect was observed during exercise testing. After withdrawal from ACE inhibition, a high incidence of clinical events occurred, suggesting a rebound phenomenon.

This article has been cited by other articles:

				P. J de Kam, A. A Voors, F. Fici, D. J van Veldhuisen, and W. H van Gilst Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era Journal of Renin-Angiotensin-Aldosterone System, December 1, 2004; 5(4): 161 - 168. [Abstract] [PDF]

				A. Prasad, R. Mincemoyer, and A. A. Quyyumi Anti-ischemic effects of angiotensin- converting enzyme inhibition in hypertension J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1116 - 1122. [Abstract] [Full Text] [PDF]

				A. F. M. van den Heuvel, P. H. J. M. Dunselman, T. Kingma, P. Verhorst, F. Boomsma, W. H. van Gilst, and D. J. van Veldhuisen Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade J. Am. Coll. Cardiol., February 1, 2001; 37(2): 470 - 474. [Abstract] [Full Text] [PDF]

				R. O. Cannon III Cardiovascular Benefit of Cholesterol-Lowering Therapy : Does Improved Endothelial Vasodilator Function Matter? Circulation, August 22, 2000; 102(8): 820 - 822. [Full Text] [PDF]

				R. Willenheimer, E. Rydberg, L. Oberg, S. Juul-Moller, and L. Erhardt ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patients with stable ischaemic heart disease and preserved left ventricular systolic function Eur. Heart J., November 2, 1999; 20(22): 1647 - 1656. [Abstract] [PDF]

				R. W. Nesto and S. Zarich Acute Myocardial Infarction in Diabetes Mellitus : Lessons Learned From ACE Inhibition Circulation, January 13, 1998; 97(1): 12 - 15. [Full Text] [PDF]